Search by property

This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.

List of results

Marucci et al. (2017): Double-blind randomized phase III study comparing a mixture of natural agents versus placebo in the prevention of acute mucositis during chemoradiotherapy for head and neck cancer + (61 patients (58.6%) developed peak grade 3 … 61 patients (58.6%) developed peak grade 3 objective mucositis during treatment, with no difference between arms (p=0.665).57 patients (54.8%) developed peak grade 3 functional mucositis during treatment with no differences between arms (p=0.442).67 patients (64.4%) developed peak grade 3 dysphagia during treatment, with no differences between arms (p = 0.132).h no differences between arms (p = 0.132).)
Halyard et al. (2007): Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4) + (?)
Lin et al. (2006): Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study + (?)
Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck + (After 12 months: No significant differences between arms)
Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck + (After 12 months: No significant differences between arms)
Chan et al. (2011): Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer + (After 12 weeks mean difference: lycopene: 0.53 ng/ml, fish oil: 0.20 ng/ml, placebo: -0.46 ng/ml; p(lycopene vs. placebo)= 0.26, not significant; p(fish oil vs. placebo) = 0.39, not significant)
Stratton et al. (2010): Oral Selenium Supplementation Has No Effect on Prostate- Specific Antigen Velocity in Men Undergoing Active Surveillance for Localized Prostate Cancer + (After 5 years: selenium arms not significantly different to placebo arm (p=0.32 and p=0.61) or to each other Subgroup of high-selenium arm with high selenium value at baseline shows higher PSA values than placebo arm (p=0.018))
Delanian et al. (2003): Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis + (After 6 month, reduction in % (SD) in each case: Pentoxyfillin + vitamin E: 39.1 (12.1), pentoxyfillin + placebo: 32.4 (20.8), vitamin E + placebo: 37.1 (15.5); placebos: 32.9 (18.5))
Delanian et al. (2003): Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis + (After 6 month, reduction in % (SD) in each case: Pentoxyfillin + vitamin E: 73.0 (7.2), pentoxyfillin + placebo: 48.6 (35.9), vitamin E + placebo: 52.8 (29.4); placebos: 50.8 (23.9))
Delanian et al. (2003): Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis + (After 6 month, reduction in % (SD) in each case: Pentoxyfillin + vitamin E: 60.2 (10.7), pentoxyfillin + placebo: 39.1 (37.4), vitamin E + placebo: 40.0 (32.0); placebos: 42.6 (17.4) ANOVA: ns., trend of a signif. interaction with vitamin E)
Upadhyaya et al. (2017): Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differential thyroid cancer: A randomized-controlled trial + (After 6 months: Vitamin E 100mg: Increas … After 6 months: Vitamin E 100mg: Increase EF right parotis (p < 0.01) and UI right submand. (p < 0.05)Vitamin E 200mg: Increase UI right parotis, both Submand. (p < 0.01)Vitamin E 300mg: Increase UF left parotis (p < 0.05) and right submand. (p < 0.01), increase UI in both submand. (p < 0.01)Usual Care: Decreasel UF in both parotis (p < 0.01) Rest: ns.All arms compared:UF: left submand.: p < 0.05UI: right parotis: p < 0.05; both submand.: p < 0.01ER: left parotis: p < 0.05otis: p < 0.05; both submand.: p < 0.01 ER: left parotis: p < 0.05)
Vitale et al. (2020): ZeOxaNMulti Trial: A Randomized, Double-Blinded, Placebo-Controlled Trial of Oral PMA-Zeolite to Prevent Chemotherapy-Induced Side Effects, in Particular, Peripheral Neuropathy + (After 6 months: Intervention n=42, Placebo … After 6 months: Intervention n=42, Placebo n=34, >8 cycles):Placebo had 70.6% and Intervention had 64.3% chemotherapy-induced peripheral neuropathy (not significant, p = 0.56)Secondary analysis showed lower chemotherapy-induced peripheral neuropathy in men in Intervention-arm compared to Placebo-Arm based on 39 patients (p = 0.047, adjusted for age, comorbidity, cycles).Intervention-arm was able to complete more cycles of chemotherapy than Placebo-arm (>8 cycles: 71.7% vs. 56.7%, p = 0.03).No difference in the severity of hematologic toxicity (p = 0.09); due to low overall toxicity, no further analyses were conducted.ll toxicity, no further analyses were conducted.)
Muecke et al. (2010): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology + (After 6 weeks post radiotherapy, levels between arms were comparable)
Laali et al. (2020): Effect of Selenium on Incidence and Severity of Mucositis during Radiotherapy in Patients with Head and Neck Cancer + (After 7 weeks no significant differences b … After 7 weeks no significant differences between the selenium arm and the placebo arm for:* mean duration of oral mucositis (grade 1–4) (p=0.27)* onset of oral mucosits (p =0.31)* recovery (day after radiation completion (p=0.80)* cumulative incidence of oral mucusitis (grade 1–4) (p=0.79)Severe oral mucositis (grade 3 or 4) was seen in 25 patients in the selenium arm and in 20 patients in the placebo arm.Addition: Development of oral mucositis in patients with selenium levels >65 mcg/l significantly delayed from baseline (p=0.04, no further explanation given)seline (p=0.04, no further explanation given))
Lian et al. (2014): Comparing the Effectiveness of Green Tea versus Topical Metronidazole Powder in Malodorous Control of Fungating Malignant Wounds in a Controlled Randomised Study + (All patients in both arms had shown reduction in malodorous score over 7 days of treatment. There was no significant difference in the improvement of odour in either arms (p>0.05).)
Lian et al. (2014): Comparing the Effectiveness of Green Tea versus Topical Metronidazole Powder in Malodorous Control of Fungating Malignant Wounds in a Controlled Randomised Study + (All patients reported an improvement in od … All patients reported an improvement in odour control after day 7 (p=0.00), impairment of daily life (p=0.00), physical discomfort (p=0.00), appetite (p=0.00) and social activities (p=0.00); but there are no significant differences between the two arms (p>0.05), except for Q5. The green tea arm rated that the odour from their wounds had significantly impacted (p=0.04) their social activities prior to treatment.) their social activities prior to treatment.)
Dale et al. (2001): Co-medication with hydrolytic enzymes in radiation therapy of uterine cervix: evidence of the reduction of acute side effects + (Although the maximum extent of gastrointes … Although the maximum extent of gastrointestinal side effects was reduced in the enzyme-arm, the difference to the control-arm was not statistically significant (p=0.12). The treatment effect was observed from 1 week after start of radiation therapy until the last follow-up visit 5 month after intervention.ollow-up visit 5 month after intervention.)
Puataweepong et. al (2009): The efficacy of oral Aloe vera juice for radiation induced mucositis in head and neck cancer patients: a double-blind placebo-controlled study + (Apparently, patients in the aloe arm had a lower incidence of severe mucositis than patients in the placebo arm. This was statistically significant (53% vs. 87%, p=0.004).)
Dyer et al. (2013): Is reflexology as effective as aromatherapy massage for symptom relief in an adult outpatient oncology population? + (Arm A: 82% to 91% on the various scales, Arm B = 68% to 86% on the various scales. No significant arm differences)
Cohen et al. (2018): Favorable Effects of a Ketogenic Diet on Physical Function, Perceived Energy, and Food Cravings in Women with Ovarian or Endometrial Cancer: A Randomized, Controlled Trial + (At 12 weeks significant between-arm differ … At 12 weeks significant between-arm difference in the desire to eat something salty, the KD arm craved salt to a greater extent than the ACS arm; difference remained after adjusting for baseline values and chemotherapy status (p = 0.03, significant); no other significant between-arm differences; no significant within-arm differences from baseline to week 12n-arm differences from baseline to week 12)
Sun et al. (2016): A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy + (At 12 weeks: Full analysis set: no difference between arms PP analysis: less fatigue/improvement of symptoms in intervention compared to placebo arm (intervention: 41.1%, placebo: 25%; χ² = 5.936; p = 0.015); Overall p = 0.0135)
Sun et al. (2016): A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy + (At 12 weeks: In full analysis set and PP-analysis significant change from baseline (p < 0.01, no further data shown).)
Büntzel et al. (2010): Selenium Substitution During Radiotherapy of Solid Tumours - Laboratory Data from Two Observation Studies in Gynaecological and Head and Neck Cancer Patients + (At 6 weeks after irradiation no significant differences; Significant differences in selenium concentrations (serum and blood) at the end of radiotherapy (p<0.0001))
Laali et al. (2020): Effect of Selenium on Incidence and Severity of Mucositis during Radiotherapy in Patients with Head and Neck Cancer + (At the end of radiation (after 7 weeks) th … At the end of radiation (after 7 weeks) there was no difference in the mean serum selenium level between the selenium arm and placebo arm (p=0.24)Based on the selenium level before radiation, developing severe oral mucositis was statistically significant postponed in patients who had selenium levels ≥ 65 mcg/L (p=0.04)ho had selenium levels ≥ 65 mcg/L (p=0.04))
Lichtmann et al. (2018): Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain + (At week 7 no significant difference for SGIC, PGIC and PSQ.)
Stauder et al. (1991): Strahlentherapeutische Nebenwirkungen bei Abdominalkrebspatienten und deren Reduktion durch hydrolytische Enzyme + (Average tolerability by doctor: enzyme-arm … Average tolerability by doctor: enzyme-arm: 1.57(0.88); control-arm: 1.38(0.86) Average tolerability by patient: enzyme-arm: 1.75(1.13); control-arm: 1.41(0.86)Therapy result by doctor: enzyme-arm: 1.94(0.79); control-arm : 1.22(0.54)Therapy result by patient: enzyme-arm: 1.89(0.85); control-arm: 1.22(0.54)e-arm: 1.89(0.85); control-arm: 1.22(0.54))

Hershman et al. (2018): Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L Carnitine + (Baseline to week 104 showed no differences between arms (p>0.05))
Hershman et al. (2018): Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L Carnitine + (Baseline to week 104 showed no differences between arms (p>0.05))

Hershman et al. (2018): Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L Carnitine + (Baseline to week 104: Intervention arm sig … Baseline to week 104: Intervention arm sign. Reduction in NTX (more severe neuropathy) compared to placebo arm (mean difference -1.39 points, 95% CI = -2.48, -0.30; p=0.01); particularly strong at week 24 (end of intervention) (-1.68, 95% CI = -3.02, -0.33), week 36 (-1.37, 95% CI = -2.69, -0.04) and week 52 (-1.83, 95% CI = -3.35, -0.32), but no difference at week 104At 104 weeks, 39.5% on the ALC arm and 34.4% on the placebo arm reported a five-point (10%) decrease from baseline; in both arms, 104-week NTX scores were statistically significantly different compared with baseline (p<0.001)Addition: Predictors: A 5-point reduction on the scale from baseline: Women aged ≥60 had an increased risk of worse neuropathy symptoms compared to those under 60 in year 1 (both arms). In arm A, weight was significantly associated with a 14% increased risk of worsening neuropathy for every 5 kg weight gain in year 1, and a 16% increased risk of worsening neuropathy per 5 kg weight in year 2. No further associations with baseline values were observed.ociations with baseline values were observed.)
Kirste et al. (2011): Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial + (Baseline: average score, placebo: 28 points, intervention: 29 points, After radiotherapy: placebo: 28 points, intervention: 27 points, Follow-up after 4 weeks: placebo: 26 points, intervention: 29 points)
Kirste et al. (2011): Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial + (Baseline: average score, placebo: 55.9 points, intervention: 54.3 points, After radiotherapy: placebo: 56.2 points, intervention: 58.6 points, Follow-up after 4 weeks: placebo: 53.8 points, intervention: 61.3 points)
Khodabakhshi et al. (2019): Feasibility, Safety, and Beneficial Effects of MCT-Based Ketogenic Diet for Breast Cancer Treatment: A Randomized Controlled Trial Study + (Body weight, BMI, fat (%) significantly lower in intervention arm compared to comparison arm (p<0.001, p<0.001, p=0.03) after 3 months)
Thamlikitkul et al. (2017): Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin–cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study + (Chemotherapy intervention vs. placebo: Dose reduction: 3% vs. 3% Delay: 9% vs. 6% No p-values have been reported.)
Karp et al. (2012): Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597 + (Collected in 865 patients in intervention … Collected in 865 patients in intervention arm and 477 in placebo arm: * Grade 1-2 toxicity in intervention arm: 31% and placebo arm: 26% of subjects* Grade ≥ 3 toxicity occurred in less than 2% of subjects in intervention arm and 3% in placebo arm* n=1 patient in placebo arm had constitutional lethal toxicity* no arm comparison performedhal toxicity * no arm comparison performed)
Sontakke et al. (2003): Ginger as an antiemetic in nausea and vomiting induced by chemotherapy: A randomized, cross-over, double blind study + (Complete control ginger-arm vs. placebo-me … Complete control ginger-arm vs. placebo-metoclopramide-arm vs. placebo-ondansetron-arm: 68% vs. 64% vs. 86%placebo-ondansetron-arm significantly higher (p<0.01), no significant difference between ginger-arm and placebo-metoclopramide-armPartial control ginger-arm vs. placebo-metoclopramide-arm vs. placebo-ondansetron-arm: 26% vs. 34% vs. 14%No control ginger-arm vs. placebo-metoclopramide-arm vs. placebo-ondansetron-arm: 6% vs. 2% vs. 0%Frequency 0-12h after chemotherapy ginger-arm vs. placebo-metoclopramide-arm vs. placebo-ondansetron-arm: 10 vs. 9 vs. 312-24h after chemotherapy ginger-arm vs. placebo-metoclopramide-arm vs. placebo-ondansetron-arm: 20 vs. 19 vs. 6In all three arms, the frequency of vomiting was significantly higher after 12-24h than after 0-12h (p<0.05)higher after 12-24h than after 0-12h (p<0.05))
Sontakke et al. (2003): Ginger as an antiemetic in nausea and vomiting induced by chemotherapy: A randomized, cross-over, double blind study + (Complete control ginger-arm vs. placebo-me … Complete control ginger-arm vs. placebo-metoclopramide-arm vs. placebo-ondansetron-arm: 62% vs. 58% vs. 86% placebo-ondansetron-arm significantly higher (p<0.01), no significant difference between ginger-arm and placebo-metoclopramide-armPartial control ginger-arm vs. placebo-metoclopramide-arm vs. placebo-ondansetron-arm: 20% vs. 20% vs. 8%No control ginger-arm vs. placebo-metoclopramide-arm vs. placebo-ondansetron-arm: 18% vs. 22% vs. 6%. placebo-ondansetron-arm: 18% vs. 22% vs. 6%)
Kessels et al. (2017): Topical Sinecatechins, 10%, Ointment for Superficial Basal Cell Carcinoma A Randomized Clinical Trial + (Complete histological tumor clearance was … Complete histological tumor clearance was observed in 1 of 21 (5%) and 2 of 21 (10%) patients in the sinecatechins and placebo group, respectively no significant difference in histological tumor clearance between the sinecatechins and placebo groups (p > .99).inecatechins and placebo groups (p > .99).)
Bairati et al. (2005): A Randomized Trial of Antioxidant Vitamins to Prevent Second Primary Cancers in Head and Neck Cancer Patients + (DFS for '''any supplementation''' beyond 3 … DFS for '''any supplementation''' beyond 3.5 years after randomization:HR = 0.85 (95% CI: 0.48, 1.50), i.e. no significant difference between intervention and placebo armDFS for '''beta-carotene + Vit. E''' beyond 3.5 years after randomization: HR = 1.11 (95% CI: 0.47, 2.61), i.e. no significant difference between intervention and placebo armDFS for '''only Vit. E''' beyond 3.5 years after randomization: HR = 0.71 (95% CI: 0.33, 1.53), i.e. no significant difference between intervention and placebo armrence between intervention and placebo arm)
Barton et al. (1998): Prospective evaluation of vitamin E for hot flashes in breast cancer survivors + (Decrease Baseline to 4 weeks in % Frequen … Decrease Baseline to 4 weeks in %Frequency of hot flashes per day:Intervention arm: 25%, Placebo arm: 22%; p = 0.90 ns.Correlation with baseline value: r = 0.12; p = 0.21 ns.Daily hot flash score (frequency with average severity):Intervention arm: 28%, Placebo arm: 20%; p = 0.68 ns.Correlation with baseline value: r = 0.13; p = 0.18 ns.--------------Crossover: Decrease 4 weeks to 8 weeks in %Frequency of hot flashes per day:Intervention arm: 0.04%, Placebo arm: 17%; p = 0.32 ns.Daily hot flash score:Intervention arm: 0.03%, Placebo arm: 25%; p = 0.24 ns.Within-subject analysis: Significant differences in frequency and hot flash score between placebo and Vit. E (both p ≤ 0.05), approximately 1 less hot flashFrequency differences between placebo and Vitamin E per week:Intervention arm (Vitamin E first then Placebo): Week 1 vs. 5: p = 0.01; Week 2-4 vs. Week 6-9: p < 0.05, sign.Placebo arm (Placebo first then Vitamin E): Week 1 vs. 5: p = 0.001; Week 2 vs. 6: p = 0.0004; Week 3 vs. 7: 0.003; Week 4 vs. 8: p = 0.07, sign.Similar results for hot flash scoreQuestion about patient preference in both arms:Vit. E: 32%, Placebo: 29%, No preference: 38%.it. E: 32%, Placebo: 29%, No preference: 38%.)
Henning et al. (2015): Randomized Clinical Trial of Brewed Green and Black Tea in Men With Prostate Cancer Prior to Prostatectomy + (Decrease in serum PSA levels higher in the … Decrease in serum PSA levels higher in the green tea arm compared to the water arm (p=0.04)PSA mean (SD) per armGreen tea arm (N=30): baseline= 9.6(5.2); after 33 days= 8.4(4.3)Water arm (N=30): baseline= 9.9(8.5); after 29 dayse= 10.0(9.0)No significant difference in changes between black tea arm and water arm (p>0.05)tween black tea arm and water arm (p>0.05))
Kessels et al. (2017): Topical Sinecatechins, 10%, Ointment for Superficial Basal Cell Carcinoma A Randomized Clinical Trial + (Decrease in tumor size was slightly greater after sinecatechins application, but the difference was nonsignificant (p = 0.15).)
Henning et al. (2015): Randomized Clinical Trial of Brewed Green and Black Tea in Men With Prostate Cancer Prior to Prostatectomy + (Detection of tea polyphenols in prostate t … Detection of tea polyphenols in prostate tissue in 32 of 34 men in the green tea arm , but not in the other arms.Detection of EGC, EC and methyl-EGC in early morning urine throughout the study in the green tea arm and at significantly lower concentrations in the black tea arm (p<0.01); no polyphenols in the water arm.(p<0.01); no polyphenols in the water arm.)
Wrbka et al. (1987): Unterstützung der Chemotherapie inoperabler Karzinome durch proteolytische Fermente + (Enzyme-arm: 68% improvement compared to control-arm: 57.69% improvement)
Gujral et al. (2001): Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers + (Enzyme-arm: no evaluation N=3, complete/go … Enzyme-arm: no evaluation N=3, complete/good response in N=32/16, moderate response N=1, poor/no response/progress N=1 Control-arm: no evaluation N=4, complete/good response N=23/15, moderate response N=5, poor/no response/progress N=0, but arm difference is not statistically significant (p=0.23) is not statistically significant (p=0.23))
Jeon et al. (2016): Effect of intravenous high dose Vitamin C on postoperative pain and morphine use after laparoscopic colectomy: A randomized controlled trial + (Estimated mean (SD) from graphic: 2, 6 and 24h post-op: at rest significantly lower in intervention compared to placebo; p's<0.05 (no values reported, only graphs) While coughing: no significant difference at any time point; p's>0.05)
Zick et al. (2008): Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting + (Examiners could not guess allocation (p=0. … Examiners could not guess allocation (p=0.27), patients could guess allocation significantly correctly (p=0.01)Reasons given: Taste: placebo: 33%; 1.0g ginger: 25%, 2.0g ginger: 9%; p=0.01Effect of the capsule: placebo: 33%, 1.0g ginger: 51%, 2.0g ginger: 16%; p=0.121.0g ginger: 51%, 2.0g ginger: 16%; p=0.12)
Cruciani et al. (2009): L-Carnitine Supplementation in Patients with Advanced Cancer and Carnitine Deficiency: A Double-Blind, Placebo-Controlled Study + (Exploratory analysis: After 4 weeks (end o … Exploratory analysis:After 4 weeks (end of phase II, PMA Analysis): significant difference for the functional subscale (b=1.9; p=0.03; unadjusted; b=2.0; p=0.002; adjusted); Intervention arm: Baseline: Mean (SD) = 11.4 (5.1) – 4 weeks: Mean (SD) = 11.0 (3.2), Placebo arm: Baseline: Mean (SD) = 10.8 (6.0) – 4 weeks: Mean (SD) = 9.2 (3.8); this difference is due to the decrease in values in the placebo arm; no direct comparison was conductedbo arm; no direct comparison was conducted)
Cruciani et al. (2009): L-Carnitine Supplementation in Patients with Advanced Cancer and Carnitine Deficiency: A Double-Blind, Placebo-Controlled Study + (Exploratory analysis: After 4 weeks (end o … Exploratory analysis:After 4 weeks (end of phase II; PMA, pattern mixture analysis): greater change for the intervention arm compared to the placebo arm (b=2.6; p=0.03; adjusted), Intervention arm: Baseline: Mean (SD) = 16.0 (8.5) – 4 weeks: Mean (SD) = 22.4 (10.7), Placebo arm: Baseline: Mean (SD) = 11.8 (6.1) – 4 weeks: Mean (SD) = 15.1 (4.8).8 (6.1) – 4 weeks: Mean (SD) = 15.1 (4.8))
Cruciani et al. (2009): L-Carnitine Supplementation in Patients with Advanced Cancer and Carnitine Deficiency: A Double-Blind, Placebo-Controlled Study + (Exploratory analysis: After 4 weeks (end o … Exploratory analysis:After 4 weeks (end of phase II, PMA Analysis): significant difference between the arms (b=2.58; p=0.003, unadjusted; b=2.7; p=0.002, adjusted), Intervention arm: Baseline: Mean (SD) = 58.2 (8.8) – 4 weeks: Mean (SD) = 64.2 (9.0), Placebo arm: Baseline: Mean (SD) = 57.0 (4.8) – 4 weeks: Mean (SD) = 50.0 (15.5); with higher values for the intervention arm and lower values for the placebo armn arm and lower values for the placebo arm)
Cruciani et al. (2009): L-Carnitine Supplementation in Patients with Advanced Cancer and Carnitine Deficiency: A Double-Blind, Placebo-Controlled Study + (Exploratory analysis: No differences between arms and/or time points for PMA-Analysis)
Campos et al. (2011): Guarana (Paullinia cupana) Improves Fatigue in Breast Cancer Patients Undergoing Systemic Chemotherapy + (FACIT-F: Significantly lower severity of f … FACIT-F: Significantly lower severity of fatigue with guarana compared to placebo, Significantly more patients with improved FACIT-F global scores on guarana at days 21 (52% versus 10%) and at day 49 (66% versus 13%) as compared with patients who received placebo.After day 1: p = 0.09After day 21: p = < 0.01After day 49: p = < 0.01 FACIT-ES: Significantly lower expression of endocrine symptoms with guarana compared to placeboIn the intragroup analysis, there were significant differences favoring guarana for the placebo–guarana arm but not for the guarana–placebo arm.After day 1: p = 0.18 After day 21: p = 0.01 After day 49: p = < 0.01After day 21: p = 0.01 After day 49: p = < 0.01)
Dos Santos Martins (2016): Placebo-Controlled, Double-Blind, Randomized Study of a Dry Guarana Extract in Patients with Head and Neck Tumors Undergoing Chemoradiotherapy: Effects on Fatigue and Quality of Life + (FACT-HN35: After first round of chemoradio … FACT-HN35:After first round of chemoradiotherapy: significant improvement in guarana group for domains pain (p = 0.0133), social eating (p = 0.0227), swallowing (p = 0.0254), coughing (p = 0.0107), and weight loss (p = 0.012)After the fourth round of chemoradiotherapy: significantly worse in domain weight loss (p = 0.0074) and greater use of a nasogastric tube (p = 0.051), in addition to increased use of analgesics (p = 0.0253) in guarana groupFACT Questionnaire: Comparison between intervention and placebo arm: trend toward worsening in the overall domain: p = .0054, significant worsening in the functional: p = .018 and symptoms domain: p = .0042 after the second cycle of chemotherapy; no significant differences, in any QOL domains, either for the guarana or placebo group, when the first measures were compared to the last assessments of each domain for each particular groupEORTC-QOL C30:No improvement in symptoms in the three domains (functional, overall, and symptoms) in the guarana group compared to the placebo groupNo further information or statistical values given, domain specific results of the EORTC questionnaire only displayed in a graphic questionnaire only displayed in a graphic)